BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 6600985)

  • 1. Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
    Kefford RF; Fox RM
    Cancer Chemother Pharmacol; 1983; 10(2):73-8. PubMed ID: 6600985
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Mitchell BS; Koller CA; Kelley WN
    Adv Exp Med Biol; 1979; 122B():347-50. PubMed ID: 317568
    [No Abstract]   [Full Text] [Related]  

  • 3. Deoxy-ATP accumulation in adenosine deaminase-inhibited human B and T lymphocytes.
    Gruber HE; Cohen AH; Firestein GS; Redelman D; Bluestein HG
    Adv Exp Med Biol; 1986; 195 Pt A():503-7. PubMed ID: 3487921
    [No Abstract]   [Full Text] [Related]  

  • 4. [Successful treatment with 2'-deoxycoformycin in a case of adult T-cell leukemia].
    Ishii M; Yamaguchi K; Yul LS; Oda T; Takatsuki K
    Rinsho Ketsueki; 1986 May; 27(5):780-3. PubMed ID: 3018324
    [No Abstract]   [Full Text] [Related]  

  • 5. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
    Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
    Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of adenosine deaminase inhibitors on the apparent rate of phosphorylation of deoxyadenosine.
    Deibel MR; Coleman MS; Hutton JJ
    Biochem Med; 1981 Jun; 25(3):288-97. PubMed ID: 6973972
    [No Abstract]   [Full Text] [Related]  

  • 7. Adenosine deaminase in malaria infection: effect of 2'-deoxycoformycin in vivo.
    Webster HK; Wiesmann WP; Pavia CS
    Adv Exp Med Biol; 1984; 165 Pt A():225-9. PubMed ID: 6609525
    [No Abstract]   [Full Text] [Related]  

  • 8. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Smyth JF; Paine RM; Jackman AL; Harrap KR; Chassin MM; Adamson RH; Johns DG
    Cancer Chemother Pharmacol; 1980; 5(2):93-101. PubMed ID: 6970630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine.
    Grever MR; Siaw MF; Coleman MS; Whisler RL; Balcerzak SP
    J Immunol; 1983 Jan; 130(1):365-9. PubMed ID: 6600187
    [No Abstract]   [Full Text] [Related]  

  • 10. Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
    Macdonald JS; Marsoni S; Bruno S; Poster D
    Recent Results Cancer Res; 1982; 80():323-30. PubMed ID: 6977170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of arabinosyladenine metabolism by 2'-deoxycoformycin in the therapy of human acute leukemia.
    Plunkett W; Nowak B; Feun LG; Benjamin RS; Keating M; Freirich EJ
    Adv Exp Med Biol; 1984; 165 Pt B():345-50. PubMed ID: 6372382
    [No Abstract]   [Full Text] [Related]  

  • 12. In vivo inhibition of adenosine deaminase by 2'-deoxycoformycin in mouse blood and leukemia L1210 cells.
    Agarwal RP
    Biochem Pharmacol; 1980 Feb; 29(2):187-93. PubMed ID: 6965857
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical, pharmacologic, and immunologic effects of 2'-deoxycoformycin.
    Cummings FJ; Crabtree GW; Wiemann MC; Spremulli EN; Parks RE; Calabresi P
    Clin Pharmacol Ther; 1988 Nov; 44(5):501-9. PubMed ID: 3263248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated T lymphocytes resist the toxic effects of the adenosine deaminase inhibitor, 2-deoxycoformycin.
    Kotb M; Veit BC
    Cell Immunol; 1982 Sep; 72(1):64-76. PubMed ID: 6983389
    [No Abstract]   [Full Text] [Related]  

  • 15. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Hershfield MS; Kurtzberg J; Harden E; Moore JO; Whang-Peng J; Haynes BF
    Proc Natl Acad Sci U S A; 1984 Jan; 81(1):253-7. PubMed ID: 6607471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenosine and hypoxic vasodilatation.
    Dóra E
    J Cereb Blood Flow Metab; 1985 Dec; 5(4):621-4. PubMed ID: 3877069
    [No Abstract]   [Full Text] [Related]  

  • 17. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
    Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemolysis in mice treated with deoxycoformycin, an inhibitor of adenosine deaminase.
    Smith CM; Belch A; Henderson JF
    Biochem Pharmacol; 1980 Apr; 29(8):1209-10. PubMed ID: 6966932
    [No Abstract]   [Full Text] [Related]  

  • 19. Energy metabolism in adenosine deaminase-inhibited human erythrocytes.
    Buc HA; Thuillier L; Hamet M; Garreau F; Moncion A; Pérignon JL
    Clin Chim Acta; 1986 Apr; 156(1):61-9. PubMed ID: 3486057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of ADA inhibition on B cell differentiation in the rat.
    Barton RW
    Adv Exp Med Biol; 1986; 195 Pt A():525-9. PubMed ID: 3524140
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.